1 completed, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Oligonucleotides, Antisense: new trials by email Literature Review of Oligonucleotides, Antisense trials Research Report on Oligonucleotides, Antisense
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients Inotersen - Amyloidosis | Phase 2 | Terminated | Brigham and Women's Hospital | 31 | 2019-02-28 | 2026-02-20 |
| The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart Isis 420915/GSK 299872 - Amyloidosis | Phase 2 | Withdrawn | Brigham and Women's Hospital | 2016-01-01 | 2016-08-10 |
Amyloidosis (2) · Pick Disease of the Brain (1) · Supranuclear Palsy, Progressive (1)
Brigham and Women's Hospital (2) · Novartis Pharmaceuticals (1)
United States (2) · Canada (1) · Germany (1) · United Kingdom (1)
Rodney Falk, MD (1) · Rodney H Falk, MD (1)